On September 25, the Global Digital Trade Fair with the theme of digital trade, known as "Number Fair," kicked off in Hangzhou, China. Astrazeneca has been deeply involved in the Number Fair for the third consecutive year, bringing a variety of cutting-edge digital medical innovations to showcase with partners, actively participating in collaborative exchanges, and jointly assisting in building China's digital medical industry innovation hub. During this Number Fair, as the chairman unit of the Digital Medical Health Industry Professional Committee, Astrazeneca supported the organization of the Digital Medical Health Industry Matchmaking Meeting and series of activities.

Zhu Lilu, Vice President of Astrazeneca China, in charge of Digitalization and Business Innovation Department, Business Strategy and Excellence Operations Department, attended this Number Fair and series of activities, delivering speeches and presentations. She stated: "In recent years, China's digital economy has flourished, leading the global forefront in areas such as 5G and artificial intelligence, with local digital medical innovation achievements and innovative enterprises emerging constantly. Astrazeneca has always been confident in the Chinese market and innovation, we will continue to leverage the advantages of Zhejiang's digital economy, work hand in hand with more partners to explore the application of digital technology in the medical field, promote innovative solutions for disease diagnosis and treatment, support the development of local innovative enterprises to go international, and contribute to the high-quality and sustainable development of the medical industry and economy."

Supporting the promotion of integrated digital diagnosis and treatment solutions to land and go global.

During the Number Fair, Astrazeneca actively collaborated with ecosystem partners to promote the landing and internationalization of innovative disease diagnosis and treatment solutions, working together to create digital, convenient, and efficient disease management solutions for patients.

The breast specialist center in Zhejiang province has been upgraded: the Breast Cancer Center of Excellence (BCCE) project, initiated by the National Cancer Center with the support of Astrazeneca, has been comprehensively upgraded in Zhejiang. The breast specialist center covers precise diagnosis, standardized treatment, patient management, and other sectors, using AI language models and innovative tools such as iMDT to promote the development of breast discipline, aiming to improve the diagnosis and treatment level of breast cancer and accelerate the sinking of high-quality medical resources.

National Standardized Metabolic Disease Management Center project goes global: Astrazeneca, together with Wise Medical, announced the launch of the National Standardized Metabolic Disease Management Center (MMC) project to support the construction of the first overseas cooperation plan, helping innovative achievements in China benefit countries along the Belt and Road Initiative concept, and promoting the common development of the global medical and health industry.

Empowering patient disease management digitally: In response to patients' needs in pharmacy services, follow-up management, adverse reaction management, innovative payment, etc., Astrazeneca, Zero Nonsense, and Alipay explore digital patient support and innovative payment models together to jointly explore integration and practical solutions.

Joining hands with leading Internet companies to promote the landing of intelligent technology applications in the medical industry.

During the meeting, astrazeneca also actively explores the diverse innovative applications of new digital technologies in the medical industry with Tencent Medical and Alibaba Cloud.

Industry's first digital customer interaction platform released: astrazeneca and Tencent Medical released the domestic industry's first 'Next-Generation Customer Interaction Platform' (NCEP), reshaping the interaction experience with doctors and other professionals, helping to improve interaction quality and efficiency, driving medical empowerment and industry transformation with digital technology.

Comprehensive exploration of generative AI applications through collaboration: astrazeneca and Alibaba Cloud have reached a comprehensive cooperation on industry generative AI, driving innovation in efficiency improvement, digitalized diagnostic treatment, personalized disease management, including the collaborative development and promotion of generative AI technology in the pharmaceutical industry, jointly exploring the combination of generative AI and Business Intelligence (BI) technology, piloting the application scenarios of AI technology, etc.

Seizing the opportunity to build a digital innovation ecosystem, boosting regional medical industry and economic development together.

AstraZeneca has always worked symbiotically with the industry, promoting China's smart health innovation center, International Life Science Innovation Park, and AstraZeneca China Golden Medical Industry Fund, the innovative 'three drivers', to continuously promote innovation development in China and globally. In Zhejiang, AstraZeneca's Hangzhou regional headquarters officially settled in 2021, with the Hangzhou International Life Science Innovation Park and Digital Medical Innovation Center being put into use simultaneously, and the AstraZeneca China Golden Medical Industry Fund Hangzhou Fund also started in 2022.

The continuous expansion of the health innovation ecosystem: Currently, the Hangzhou International Life Science Innovation Park with a focus on 'digital medical' has attracted 29 companies focused on digital medical fields like Hepure Bio, Yi'er Hearing, and Geno Medical. During this Expo, 7 innovative enterprises have joined.

Empowering local companies with the innovative 'three drivers': As an invested company by AstraZeneca China Golden Medical Industry Fund, the AI unicorn company Deep Wise Medical launched a multimodal artificial intelligence MDT clinical decision-making platform during this Expo, empowering the development of personalized treatment plans with AI. Additionally, as an innovation park enterprise, Senmey Medical reached a cooperation with Hangzhou Traditional Chinese Medicine Hospital to jointly explore the transformation of the IgA Nephropathy prognosis model based on AI technology, enhancing the level of primary care in integrated Chinese and Western medicine nephrology.

During this Expo, AstraZeneca, along with many partners, appeared at the digital medical featured pavilion, showcasing a comprehensive range of 6 integrated diagnosis and treatment solutions covering metabolic, respiratory, tumor, primary care, and other disease areas in 5 exhibition areas, nearly 20 digital medical achievements covering the full cycle of disease management from screening, diagnosis, treatment, to management, as well as over 10 cutting-edge digital medical technologies and experiential projects like AR glasses for pulmonary function testing, BCCE AI Smart Doctor, and digital virtual humans.

In the future, Astrazeneca will continue to actively respond to the 'digital economy' global strategy, deepen its commitment to China, uphold the concept of 'patient-centered' philosophy, empower digital intelligence to promote the high-quality and sustainable development of China's medical industry and economy, and contribute to 'Health China 2030'.